TSX:GUD (Canada)
Business Description
Knight Therapeutics Inc
NAICS : 325412
SIC : 3741
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Compare
Compare
Traded in other countries / regions
GUD.Canada
•
04K.Germany
•
KHTRF.USA
Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.64 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 1.22 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.05 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 182.2 | |||||
| 3-Year EBITDA Growth Rate | 28.8 | |||||
| 3-Year EPS without NRI Growth Rate | -8.6 | |||||
| 3-Year FCF Growth Rate | -178.2 | |||||
| 3-Year Book Growth Rate | -0.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.17 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.98 | |||||
| 9-Day RSI | 54.9 | |||||
| 14-Day RSI | 55.43 | |||||
| 6-1 Month Momentum % | -2.17 | |||||
| 12-1 Month Momentum % | 2.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | |||||
| Quick Ratio | 2.1 | |||||
| Cash Ratio | 1.4 | |||||
| Days Inventory | 182.51 | |||||
| Days Sales Outstanding | 87.6 | |||||
| Days Payable | 180.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 6.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.74 | |||||
| Operating Margin % | -4.18 | |||||
| Net Margin % | -2.56 | |||||
| ROE % | -0.79 | |||||
| ROA % | -0.66 | |||||
| ROIC % | -0.51 | |||||
| ROC (Joel Greenblatt) % | -21.86 | |||||
| ROCE % | -1.79 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.64 | |||||
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| Price-to-Operating-Cash-Flow | 17.1 | |||||
| EV-to-EBIT | -32.86 | |||||
| EV-to-EBITDA | 13.67 | |||||
| EV-to-Revenue | 2.01 | |||||
| EV-to-Forward-Revenue | 2 | |||||
| EV-to-FCF | -2.86 | |||||
| Price-to-Projected-FCF | 2.92 | |||||
| Price-to-Net-Current-Asset-Value | 3.99 | |||||
| Price-to-Net-Cash | 141.5 | |||||
| Earnings Yield (Greenblatt) % | -3.04 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 261.216 | ||
| EPS (TTM) (C$) | -0.06 | ||
| Beta | 0.5 | ||
| Volatility % | 13.23 | ||
| 14-Day RSI | 55.43 | ||
| 14-Day ATR (C$) | 0.128438 | ||
| 20-Day SMA (C$) | 5.5955 | ||
| 12-1 Month Momentum % | 2.85 | ||
| 52-Week Range (C$) | 5.03 - 5.85 | ||
| Shares Outstanding (Mil) | 114.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Knight Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||